2949 Articles

Transitioning agents that are effective in advanced disease to earlier disease settings is a common pathway for drug development and a concept that has been applied to multiple agents across several tumor types.

Limited data about biomarkers are available to predict the outcomes of targeted therapy in metastatic renal cell carcinoma (mRCC). Circulating cell-free DNA (CFD) is elevated in various cancers.

We performed a prospective study of patients with mRCC who received targeted therapy in the Soroka Medical Center between 2013 and 2015.